Sun Pharma has reported a total income of Rs. 9848.82 crore during the period ended September 30, 2021, as compared to Rs. 9871.26 crore during the period ended June 30, 2021. The company has reported a total income of Rs.8808.91 crores during the period ended September 30, 2020.

It has posted a net profit of Rs. 2088.73 crore for the period ended September 30, 202,1 as against a net profit of Rs. 1408.65 crore for the period ended June 30, 2021.It has posted a net profit of Rs.1948.38 crore for the period ended September 30, 2020.

Sun Pharma has reported a total income of Rs.19720.08 crore during the 6 months ended September 30, 2021, as compared to Rs.16547.95 crore during the 6 months ended September 30, 2020.

Dilip Shanghvi, Managing Director of the company said, “Following our good Q1 performance, we have sustained the positive momentum in Q2 with a topline growth of 13% YoY, driven by broad-based growth across multiple geographies. Our global speciality business has grown by 43% over Q2 last year. Ilumya has grown both YoY and sequentially. Our India business continues to do well with a growth of 26% YoY. We remain steadfast in our focus on growing our overall business and simultaneously strengthening our global speciality portfolio. The recent launch of Winlevi in the US and Ilumya in Canada is a step forward in this direction.”